Genome-wide association study of abnormal elevation of ALT in patients exposed to atabecestat

Abstract Background Atabecestat, a potent brain penetrable BACE1 inhibitor that reduces CSF amyloid beta (Aβ), was developed as an oral treatment for Alzheimer’s disease (AD). Elevated liver enzyme adverse events were reported in three studies although only one case met Hy’s law criteria to predict...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Qingqin S. Li, Stephan Francke, Jan Snoeys, John Thipphawong, Gary Romano, Gerald P. Novak
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2023-09-01
Edice:	BMC Genomics
Témata:	GWAS ALT elevation Atabecestat
On-line přístup:	https://doi.org/10.1186/s12864-023-09625-6
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!